Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

NCT04414969 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Immune Checkpoint Inhibitor
Chemotherapy Effect
Epigenetic Disorder
NK/T-cell Lymphoma of Nasal Cavity

Interventions

DRUG: Anti-PD-1 antibody+Peg-Asparaginase+Chidamide

Sponsor

Hunan Cancer Hospital